Alvotech (ALVO)
ALVO Stock Price Chart
Explore Alvotech interactive price chart. Choose custom timeframes to analyze ALVO price movements and trends.
ALVO Company Profile
Discover essential business fundamentals and corporate details for Alvotech (ALVO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
16 Jun 2022
Employees
1.01k
Website
https://www.alvotech.comCEO
Lisa Graver
Description
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
ALVO Financial Timeline
Browse a chronological timeline of Alvotech corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.04, while revenue estimate is $111.50m.
Earnings released on 6 May 2026
EPS came in at -$0.09 falling short of the estimated -$0.07 by -28.57%, while revenue for the quarter reached $105.90m , missing expectations by -5.77%.
Earnings released on 18 Mar 2026
EPS came in at -$0.37 falling short of the estimated -$0.01 by -6.33k%, while revenue for the quarter reached $173.20m , beating expectations by +6.79%.
Earnings released on 12 Nov 2025
EPS came in at -$0.02 falling short of the estimated $0.05 by -140.00%, while revenue for the quarter reached $113.95m , missing expectations by -30.91%.
Earnings released on 13 Aug 2025
EPS came in at $0.14 surpassing the estimated -$0.26 by +153.85%, while revenue for the quarter reached $173.24m , beating expectations by +11.37%.
Earnings released on 7 May 2025
EPS came in at $0.35 surpassing the estimated -$0.17 by +305.88%, while revenue for the quarter reached $132.77m , beating expectations by +10.17%.
Earnings released on 26 Mar 2025
EPS came in at -$0.24 surpassing the estimated -$0.39 by +38.46%, while revenue for the quarter reached $151.21m , beating expectations by +54.31%.
Earnings released on 13 Nov 2024
EPS came in at $0.19 surpassing the estimated -$0.06 by +401.59%, while revenue for the quarter reached $489.68m , beating expectations by +476.10%.
Earnings released on 15 Aug 2024
EPS came in at $0.28 surpassing the estimated -$0.28 by +200.00%, while revenue for the quarter reached $198.75m , beating expectations by +136.61%.
Earnings released on 21 May 2024
EPS came in at -$0.89 falling short of the estimated -$0.08 by -972.29%, while revenue for the quarter reached $12.43m .
Earnings released on 20 Mar 2024
EPS came in at -$1.22 falling short of the estimated $0.15 by -913.33%, while revenue for the quarter reached $53.39m , missing expectations by -21.49%.
Earnings released on 28 Nov 2023
EPS came in at -$0.82 falling short of the estimated -$0.29 by -182.76%, while revenue for the quarter reached $17.79m , missing expectations by -58.63%.
Earnings released on 30 Aug 2023
EPS came in at -$0.43 falling short of the estimated -$0.14 by -207.14%, while revenue for the quarter reached $4.39m , missing expectations by -89.55%.
Earnings released on 19 May 2023
EPS came in at -$0.33 , while revenue for the quarter reached $15.86m .
Earnings released on 1 Mar 2023
EPS came in at -$1.29 , while revenue for the quarter reached $23.86m .
Earnings released on 16 Nov 2022
EPS came in at -$0.04 , while revenue for the quarter reached $19.05m .
Earnings released on 1 Sept 2022
EPS came in at -$0.54 , while revenue for the quarter reached $39.67m .
Earnings released on 16 May 2022
EPS came in at -$0.32 , while revenue for the quarter reached $452.00k .
Earnings released on 30 Mar 2022
EPS came in at $1.28 , while revenue for the quarter reached $34.76m .
Earnings released on 15 Nov 2021
EPS came in at -$0.41 , while revenue for the quarter reached $536.00k .
Earnings released on 16 Aug 2021
EPS came in at -$0.01 , while revenue for the quarter reached $1.18m .
ALVO Stock Performance
Access detailed ALVO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
